DepressionNCT06997549
Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
An observational study of Depression and OCD, run by Neuronetics at 1 site in United States.
Trial summary
The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness Read more about this study
- Who is it for?
- Ages 5 to 100 years
- Conditions the study is for
- Depression, OCD, Anxiety Depression
- What is being tested?
- Patients treated with NeuroStar TMS and Patients treated with Esketamine
- Type of treatment
- Medical device
- How many people
- 12,000 participants
- Where
- 1 siteUnited States
- Study dates
- 15 May 2025to Dec 2035
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 100 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Individuals who received mental health treatment at a Greenbrook Center and the data is available in their database.
Who may be able to join
- Male or female reported in database and not an invalid entry
- Age reported and not an invalid entry
- Treatment date in 2011 or later.
Who cannot join
- Incomplete information on treatment parameters
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Neuronetics
Malvern, Pennsylvania, 19355
Eleanor Cole
About this study
The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness
Read the detailed description
this is a retrospective data analysis study that will utilize the already collected data as clinical care and will help understand the utilization and efficacy of various treatment options available for various mental heath conditions.
- Conditions
- Depression, OCD, Anxiety Depression
- Being tested
- Patients treated with NeuroStar TMS, Patients treated with Esketamine
- Medical subject headings
- Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patients treated with NeuroStar TMSDevice
Also called TMS
non-invasive brain stimulation device
Patients treated with EsketamineDrug
Also called spravato
nasal spray for treating depression
What is being measured
The primary outcome is the main question the study is designed to answer.
change in clinical outcome scores from baseline to post treatment
real-world efficacy of NeuroStar TMS as compared to Esketamine in reducing patients' symptoms, reduction in clinical assessment score like PHQ-9
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2025
- Study start15 May 2025
- Primary completionDec 2035 (estimated)
- Study completionDec 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DepressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 12,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Neuronetics
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Eleanor Cole, PhD, Study director, Neuronetics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06997549
- Sponsor's protocol ID
- 11-10002-000
- Status last verified
- Apr 2026
- First submitted
- 21 May 2025
- Last updated
- 9 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
- ClinicalTrials.gov ID
- NCT06997549
- Acronym / sponsor ID
- 11-10002-000
- Conditions
- Depression, OCD, Anxiety Depression
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 12,000 participants (estimated)
- Lead sponsor
- NeuroneticsUniversity, hospital or other
- Study start
- 15 May 2025 (actual)
- Primary completion
- Dec 2035 (estimated)
- Study completion
- Dec 2035 (estimated)
- First posted
- 30 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness
Detailed description
this is a retrospective data analysis study that will utilize the already collected data as clinical care and will help understand the utilization and efficacy of various treatment options available for various mental heath conditions.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 5 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Individuals who received mental health treatment at a Greenbrook Center and the data is available in their database.
Key inclusion criteria (3 listed)
- Male or female reported in database and not an invalid entry
- Age reported and not an invalid entry
- Treatment date in 2011 or later.
Key exclusion criteria (1 listed)
- Incomplete information on treatment parameters
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patients treated with NeuroStar TMSAlso: TMSnon-invasive brain stimulation device | Device | – |
| Patients treated with EsketamineAlso: spravatonasal spray for treating depression | Drug | – |
Primary outcome
change in clinical outcome scores from baseline to post treatment
Time frame: 8 weeks
real-world efficacy of NeuroStar TMS as compared to Esketamine in reducing patients' symptoms, reduction in clinical assessment score like PHQ-9
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Apr 2026.
Related trials for Depression
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Recruiting
Cultural Adaptation of an Online Parenting Intervention to Reduce the Risk of Depression and Anxiety in Adolescents
Risk of Depression and Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Eleanor Cole, PhD study director
Neuronetics
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Depression and OCD, run by Neuronetics at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Neha Goyal (7635281599, neha.goyal@neurostar.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
change in clinical outcome scores from baseline to post treatment (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2026.